How would you treat a patient with metastatic NSCLC on pembrolizumab with a sustained complete response, now with 2 isolated small liver lesions?  

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at St Louis Cancer Care LLP
FYI, supporting evidence for this approach, i.e., ...
Sign in or Register to read more